Citizens Jmp Forecasts Strong Price Appreciation for Precigen (NASDAQ:PGEN) Stock

Precigen (NASDAQ:PGEN) had its price target increased by investment analysts at Citizens Jmp from $11.00 to $12.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp‘s price objective would indicate a potential upside of 168.46% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Thursday, October 15th. Citigroup reaffirmed a “market outperform” rating on shares of Precigen in a research report on Thursday. B. Riley Financial initiated coverage on shares of Precigen in a research note on Friday, September 25th. They set a “buy” rating and a $12.00 price target on the stock. HC Wainwright boosted their price target on shares of Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Raymond James Financial set a $12.00 price objective on shares of Precigen in a research note on Thursday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Precigen Stock Up 5.9%

Shares of PGEN traded up $0.25 during mid-day trading on Thursday, reaching $4.47. The company’s stock had a trading volume of 9,235,321 shares, compared to its average volume of 5,403,828. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 3.89. Precigen has a 12-month low of $3.04 and a 12-month high of $8.98. The stock has a market cap of $1.59 billion, a PE ratio of 44.70 and a beta of 1.01. The company’s 50 day moving average is $6.98 and its 200 day moving average is $5.28.

Precigen (NASDAQ:PGEN) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The firm had revenue of $74.15 million during the quarter, compared to analysts’ expectations of $71.55 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%. The firm’s revenue was up 2437.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.06) earnings per share. Equities analysts anticipate that Precigen will post 0.23 EPS for the current fiscal year.

Insider Activity at Precigen

In other news, Director Jeffrey Kindler sold 185,000 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total value of $1,376,400.00. Following the completion of the sale, the director directly owned 17,100 shares of the company’s stock, valued at approximately $127,224. This represents a 91.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Rutul Shah sold 15,342 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $7.50, for a total transaction of $115,065.00. Following the transaction, the chief operating officer owned 468,865 shares in the company, valued at approximately $3,516,487.50. This trade represents a 3.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 235,000 shares of company stock valued at $1,751,400 over the last three months. Corporate insiders own 41.40% of the company’s stock.

Institutional Investors Weigh In On Precigen

Several hedge funds have recently made changes to their positions in PGEN. Carolina Wealth Advisors LLC purchased a new stake in shares of Precigen during the third quarter worth approximately $46,000. USA Financial Formulas acquired a new position in Precigen in the 3rd quarter valued at $52,000. Sterling Capital Management LLC increased its stake in Precigen by 847.8% in the 3rd quarter. Sterling Capital Management LLC now owns 6,426 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 5,748 shares during the period. State of Wyoming acquired a new position in Precigen in the 1st quarter valued at $27,000. Finally, Royal Bank of Canada raised its position in Precigen by 102.6% during the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after buying an additional 5,426 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Trending Headlines about Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts for Precigen across Q4 2026 and each quarter of 2027, while maintaining a Buy rating and an $18 price target. HC Wainwright estimates and rating
• Positive Sentiment: Citizens JMP raised its price target from $11 to $12 and reiterated a Market Outperform rating, adding to the bullish analyst outlook. Citizens JMP price target
• Positive Sentiment: Precigen’s Q3 revenue of $74.1 million topped the cited FactSet estimate of $71.5 million. The reported $0.08 per-share earnings beat some estimates but fell short of the higher Zacks consensus, making the earnings picture mixed. Q3 revenue results
• Negative Sentiment: A valuation analysis argues that PGEN may already be fully priced based on current earnings, which could limit further upside if future growth does not meet expectations. Precigen valuation analysis

Precigen Company Profile

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.